Eli Lilly | LLY - Los Gastos De Explotación





Los Gastos De Explotación Cambio Fecha
AbbVie USD 10.52B 258M 2026-09
Abbott USD 11.66B 1.2B 2026-09
ALKERMES USD 1.86B 56.17M 2026-09
Amgen USD 5.69B 6B 2026-09
AstraZeneca USD 11.55B 674M 2026-09
Baxter International USD 6.5B 3.82B 2026-09
Biogen USD 2.32B 663.6M 2026-09
Bristol-Myers Squibb USD 23.4B 1.08B 2026-09
Coherus Biosciences USD 51.83M 2.48M 2025-12
Drreddys Laboratories INR 73.9B 431M 2026-09
Eli Lilly USD 10.52B 496M 2026-06
Gilead Sciences USD 13.04B 9.09B 2026-09
GlaxoSmithKline GBP 6.03B 227M 2026-09
Glaxosmithkline GBP 6.76B 1.42B 2026-09
J&J USD 18.93B 1.09B 2026-09
Medtronic USD 7.92B 203M 2026-06
Merck USD 10.75B 5.02B 2026-09
Neurocrine Biosciences USD 779.7M 40.6M 2026-09
Novartis USD 9.88B 325M 2026-09
Novartis USD 13.19B 3.9B 2026-09
Novo Nordisk DKK 44.73B 7.52B 2026-06
Perrigo USD 961.4M 670.9M 2026-09
Pfizer USD 89B 3.81B 2026-09
Phibro Animal Health USD 417.67M 1.04B 2026-09
Prestige Brands USD 213.19M 7.06M 2026-06
Regeneron Pharmaceuticals USD 33.5B 1.79B 2026-09
Roche Holding CHF 18.9B 2.12B 2026-06
Sanofi EUR 10.51B 598M 2026-09
Sanofi EUR 9.92B 941M 2026-06
United Therapeutics USD 6.28B 124.3M 2026-09
Zoetis USD 3.15B 85M 2026-06